Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Cash from Operations: 2021-2025

Historic Cash from Operations for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$14.3 million.

  • ProQR Therapeutics N.V's Cash from Operations fell 130.23% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.7 million, marking a year-over-year decrease of 61.41%. This contributed to the annual value of -$41.8 million for FY2024, which is 279.12% down from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Cash from Operations stood at -$14.3 million for Q3 2025, which was down 10.83% from -$12.9 million recorded in Q2 2025.
  • ProQR Therapeutics N.V's Cash from Operations' 5-year high stood at $48.7 million during Q2 2023, with a 5-year trough of -$23.0 million in Q1 2022.
  • Its 3-year average for Cash from Operations is -$5.1 million, with a median of -$10.5 million in 2023.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Cash from Operations tumbled by 520.19% in 2022, and later spiked by 407.47% in 2023.
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's Cash from Operations stood at $4.3 million in 2021, then plummeted by 520.19% to -$18.2 million in 2022, then surged by 68.53% to -$5.7 million in 2023, then slumped by 124.43% to -$12.9 million in 2024, then crashed by 130.23% to -$14.3 million in 2025.
  • Its last three reported values are -$14.3 million in Q3 2025, -$12.9 million for Q2 2025, and -$16.6 million during Q1 2025.